Purple Biotech Ltd ADR (PPBT)

$1.46 +0.03 (2.10%)
Market Cap 1.33M
Revenue (ttm) 0.00
Net Income (ttm) -26.39M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 43,600
Avg Vol 1,626,312
Day's Range N/A - N/A
Shares Out 929,000.00
Stochastic %K 22%
Beta 0.71
Analysts Sell
Price Target $17.00

Company Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 933 3121
Fax: 972 3 509 7196
Address:
4 Oppenheimer Street, Science Park, Rehovot, Israel
vinland
vinland Sep. 22 at 9:20 PM
$PPBT AH smoke signals but now i tag
0 · Reply
65creedmore
65creedmore Sep. 22 at 6:27 PM
$PPBT https://youtube.com/shorts/0LB41FKypG8?is=dhNt8irz_YRVK1hZ
0 · Reply
Stocktelligence
Stocktelligence Sep. 22 at 2:24 PM
$PPBT
0 · Reply
jdlman
jdlman Sep. 22 at 6:37 AM
$PPBT $AZTR $BJDX All these are scams
1 · Reply
LuckyBoy27
LuckyBoy27 Sep. 21 at 5:07 PM
$PPBT is the still getting paycheck ? Completely gone Dark after misleading investors
2 · Reply
coinspitter
coinspitter Sep. 21 at 1:55 PM
$PPBT
0 · Reply
GildedAge01
GildedAge01 Sep. 21 at 1:36 PM
$PPBT this one is in free fall
0 · Reply
Stock_Boomer
Stock_Boomer Sep. 21 at 1:47 AM
$PPBT - Set PUT @ 0.49 ---- E.Z. Monday!
0 · Reply
Stock_Boomer
Stock_Boomer Sep. 21 at 12:18 AM
$PPBT Go Go 0.99 - EZ Shorting!
0 · Reply
Winorbust
Winorbust Sep. 20 at 10:05 PM
$PPBT I agree. Everyone who ignored the warnings or the DD that shows multiple reverse splits and dilution deserve to lose every single penny they put in. But it’s interesting that DR.HIM disappeared again. Or maybe blocked people again. He’s a paid pumper or works for PPBT just like Smitty… they pump and then when it goes down they either make excuses or disappear until the next green so they can pump and pretend like it didn’t go down
0 · Reply
Latest News on PPBT
Why Is Purple Biotech (PPBT) Stock 42% Up Today?

2026-09-02T13:22:58.000Z - 20 days ago

Why Is Purple Biotech (PPBT) Stock 42% Up Today?

Purple Biotech issued notice of allowance from USPTO

2026-09-02T11:50:21.000Z - 20 days ago

Purple Biotech issued notice of allowance from USPTO

New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies

Wed, 02 Sep 2026 07:30:00 -0400 - 20 days ago

New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies

Purple Biotech price target lowered to $17 from $30 at H.C. Wainwright

2026-08-07T16:40:30.000Z - 6 weeks ago

Purple Biotech price target lowered to $17 from $30 at H.C. Wainwright

Purple Biotech presents new IM1240 data at EACR

2026-06-11T12:12:56.000Z - 3 months ago

Purple Biotech presents new IM1240 data at EACR

Purple Biotech files $200M mixed securities shelf

2026-05-20T21:35:38.000Z - 4 months ago

Purple Biotech files $200M mixed securities shelf

Purple Biotech reports IM1240 demonstrates potent anti-tumor activity

2026-04-27T11:44:09.000Z - 4 months ago

Purple Biotech reports IM1240 demonstrates potent anti-tumor activity

Purple Biotech announces collaboration with Converge Bio

2026-03-25T12:17:12.000Z - 6 months ago

Purple Biotech announces collaboration with Converge Bio

Purple Biotech regains compliance with Nasdaq

2026-03-17T11:31:37.000Z - 6 months ago

Purple Biotech regains compliance with Nasdaq

Purple Biotech price target lowered to $30 from $34 at H.C. Wainwright

2026-03-13T17:47:18.000Z - 6 months ago

Purple Biotech price target lowered to $30 from $34 at H.C. Wainwright

Purple Biotech CEO Gil Efron to step down in August

2026-03-13T12:13:32.000Z - 6 months ago

Purple Biotech CEO Gil Efron to step down in August

Purple Biotech reports Q4 EPS ($19.85) vs. ($2.00) last year

2026-03-13T12:07:41.000Z - 6 months ago

Purple Biotech reports Q4 EPS ($19.85) vs. ($2.00) last year

Purple Biotech Announces CEO Transition

Fri, 13 Mar 2026 08:04:00 -0400 - 6 months ago

Purple Biotech Announces CEO Transition

Purple Biotech trading halted, news pending

2026-02-28T00:50:34.000Z - 6 months ago

Purple Biotech trading halted, news pending

Purple Biotech to implement ADS ratio change

2026-02-25T22:35:50.000Z - 6 months ago

Purple Biotech to implement ADS ratio change

Purple Biotech Announces Plan to Implement ADS Ratio Change

Wed, 25 Feb 2026 16:20:00 -0500 - 6 months ago

Purple Biotech Announces Plan to Implement ADS Ratio Change

Purple Biotech completes toxicology study of IM1240

2026-01-07T13:05:42.000Z - 8 months ago

Purple Biotech completes toxicology study of IM1240

Purple Biotech’s antibody platform shows anti-tumor activity

2025-12-11T12:26:28.000Z - 9 months ago

Purple Biotech’s antibody platform shows anti-tumor activity

Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress

Dec 4, 2025, 7:00 AM EST - 9 months ago

Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress

Purple Biotech reports Q3 EPS (29c) vs. (39c) last year

2025-11-14T13:11:08.000Z - 10 months ago

Purple Biotech reports Q3 EPS (29c) vs. (39c) last year

Purple Biotech sees cash runway into 1H27

2025-11-14T13:10:49.000Z - 10 months ago

Purple Biotech sees cash runway into 1H27

Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 14, 2025, 8:00 AM EST - 10 months ago

Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update

Why Is Purple Biotech Stock (PPBT) Up 95% Today?

2025-10-29T13:21:27.000Z - 10 months ago

Why Is Purple Biotech Stock (PPBT) Up 95% Today?

Purple Biotech achieves manufacturing milestone for IM1240

2025-10-29T11:41:23.000Z - 10 months ago

Purple Biotech achieves manufacturing milestone for IM1240

Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

Oct 29, 2025, 7:33 AM EDT - 10 months ago

Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

Purple Biotech receives noncompliance notification from Nasdaq

2025-10-20T20:05:22.000Z - 11 months ago

Purple Biotech receives noncompliance notification from Nasdaq

Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification

Oct 20, 2025, 4:00 PM EDT - 11 months ago

Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification

Purple Biotech receives intention to grant a European patent covering NT219

2025-09-10T12:10:31.000Z - 1 year ago

Purple Biotech receives intention to grant a European patent covering NT219

Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

Sep 5, 2025, 4:00 PM EDT - 1 year ago

Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

Purple Biotech prices 5.99M ADSs at $1.00 in public offering

2025-09-04T13:20:09.000Z - 1 year ago

Purple Biotech prices 5.99M ADSs at $1.00 in public offering

Purple Biotech announces new data on IM1240

2025-09-04T11:20:09.000Z - 1 year ago

Purple Biotech announces new data on IM1240

PPBT

Purple Biotech expands CAPTN-3 portfolio with IM1305

2025-09-03T11:06:00.000Z - 1 year ago

Purple Biotech expands CAPTN-3 portfolio with IM1305

PPBT

Purple Biotech files to sell 2.7M American Depositary Shares, warrants

2025-08-29T13:20:14.000Z - 1 year ago

Purple Biotech files to sell 2.7M American Depositary Shares, warrants

PPBT

Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 7:00 AM EDT - 1 year ago

Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Purple Biotech reports Q2 EPS 40c vs $1.80 last year

2025-08-06T11:21:25.000Z - 1 year ago

Purple Biotech reports Q2 EPS 40c vs $1.80 last year

PPBT

Purple Biotech Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Purple Biotech Reports Second Quarter 2025 Financial Results

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Jul 23, 2025, 7:00 AM EDT - 1 year ago

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

Jun 23, 2025, 7:00 AM EDT - 1 year ago

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

Purple Biotech Reports First Quarter 2025 Financial Results

May 21, 2025, 7:10 AM EDT - 1 year ago

Purple Biotech Reports First Quarter 2025 Financial Results

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

May 12, 2025, 7:30 AM EDT - 1 year ago

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Apr 28, 2025, 8:28 AM EDT - 1 year ago

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Mar 10, 2025, 8:57 AM EDT - 1 year ago

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Feb 18, 2025, 7:00 AM EST - 1 year ago

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 5, 2024, 7:13 AM EST - 1 year ago

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 3, 2024, 8:23 AM EST - 1 year ago

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Why Is Purple Biotech Stock Trading Higher On Monday?

Dec 2, 2024, 9:18 AM EST - 1 year ago

Why Is Purple Biotech Stock Trading Higher On Monday?

Purple Biotech Reports Third Quarter 2024 Financial Results

Nov 15, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Reports Third Quarter 2024 Financial Results

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Nov 4, 2024, 7:50 AM EST - 1 year ago

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 25, 2024, 7:20 AM EDT - 1 year ago

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Sep 18, 2024, 6:30 AM EDT - 2 years ago

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Aug 30, 2024, 7:00 AM EDT - 2 years ago

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 16, 2024, 8:12 AM EDT - 2 years ago

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Jul 25, 2024, 7:35 AM EDT - 2 years ago

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Jul 10, 2024, 7:30 AM EDT - 2 years ago

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Jul 2, 2024, 4:00 PM EDT - 2 years ago

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Jul 1, 2024, 9:00 AM EDT - 2 years ago

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Jun 27, 2024, 7:45 AM EDT - 2 years ago

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

Jun 1, 2024, 8:00 AM EDT - 2 years ago

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

Purple Biotech Reports First Quarter 2024 Financial Results

May 21, 2024, 7:30 AM EDT - 2 years ago

Purple Biotech Reports First Quarter 2024 Financial Results

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Apr 25, 2024, 7:00 AM EDT - 2 years ago

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Mar 14, 2024, 7:30 AM EDT - 2 years ago

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Mar 5, 2024, 7:55 AM EST - 2 years ago

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Feb 27, 2024, 7:00 AM EST - 2 years ago

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Feb 13, 2024, 7:00 AM EST - 2 years ago

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Feb 1, 2024, 7:30 AM EST - 2 years ago

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Dec 20, 2023, 8:05 AM EST - 2 years ago

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Dec 14, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Purple Biotech Reports Third Quarter 2023 Financial Results

Nov 21, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Reports Third Quarter 2023 Financial Results

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Oct 19, 2023, 3:55 PM EDT - 2 years ago

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Purple Biotech Announces $5 Million Registered Direct Offering

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Purple Biotech Announces $5 Million Registered Direct Offering

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

Oct 6, 2023, 7:50 AM EDT - 2 years ago

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Oct 3, 2023, 7:50 AM EDT - 2 years ago

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Purple Biotech Reports Second Quarter 2023 Financial Results

Aug 22, 2023, 9:29 AM EDT - 3 years ago

Purple Biotech Reports Second Quarter 2023 Financial Results

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

Jul 11, 2023, 8:15 AM EDT - 3 years ago

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

May 16, 2023, 4:00 PM EDT - 3 years ago

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

Apr 19, 2023, 8:15 AM EDT - 3 years ago

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

vinland
vinland Sep. 22 at 9:20 PM
$PPBT AH smoke signals but now i tag
0 · Reply
65creedmore
65creedmore Sep. 22 at 6:27 PM
$PPBT https://youtube.com/shorts/0LB41FKypG8?is=dhNt8irz_YRVK1hZ
0 · Reply
Stocktelligence
Stocktelligence Sep. 22 at 2:24 PM
$PPBT
0 · Reply
jdlman
jdlman Sep. 22 at 6:37 AM
$PPBT $AZTR $BJDX All these are scams
1 · Reply
LuckyBoy27
LuckyBoy27 Sep. 21 at 5:07 PM
$PPBT is the still getting paycheck ? Completely gone Dark after misleading investors
2 · Reply
coinspitter
coinspitter Sep. 21 at 1:55 PM
$PPBT
0 · Reply
GildedAge01
GildedAge01 Sep. 21 at 1:36 PM
$PPBT this one is in free fall
0 · Reply
Stock_Boomer
Stock_Boomer Sep. 21 at 1:47 AM
$PPBT - Set PUT @ 0.49 ---- E.Z. Monday!
0 · Reply
Stock_Boomer
Stock_Boomer Sep. 21 at 12:18 AM
$PPBT Go Go 0.99 - EZ Shorting!
0 · Reply
Winorbust
Winorbust Sep. 20 at 10:05 PM
$PPBT I agree. Everyone who ignored the warnings or the DD that shows multiple reverse splits and dilution deserve to lose every single penny they put in. But it’s interesting that DR.HIM disappeared again. Or maybe blocked people again. He’s a paid pumper or works for PPBT just like Smitty… they pump and then when it goes down they either make excuses or disappear until the next green so they can pump and pretend like it didn’t go down
0 · Reply
Winorbust
Winorbust Sep. 20 at 10:02 PM
$PPBT yep! Rinse and repeat… dilute, reverse split, dilute, reverse split. That’s how this scam has been run All while management gets rich with their insane salaries
0 · Reply
GildedAge01
GildedAge01 Sep. 20 at 6:10 PM
$PPBT once it sees $1.20 it will rush to .99 and then reverse split in 5-6 months
0 · Reply
LetItRip675
LetItRip675 Sep. 19 at 4:30 PM
$PPBT I need a cigarette
0 · Reply
YamiDawg
YamiDawg Sep. 18 at 11:28 PM
$PPBT Oh is the SP going down. What under a buck. Then RS. No way. We never seen this play before. Let’s Pump It Pump It PumpIt. lol. Nah same shit as every year. Hero or Zero. But thank God Zero is finally closing in. Fuck You KTOV PPBT Scam Fuckers. Let’s get an SAB or 2. Wait we got those. How can we fail. By design. FRAUD!!!!! So glad the new bag holders didn’t listen and now going down with us. Stupid fucks deserve to lose it all. The millions lost by longs her warning them. Fuckem. We didn’t listen and lost it all. No surprise they didn’t. But PPBT wins at retails losss. Please be Zero in 2027. End the pain.
1 · Reply
Stock_Boomer
Stock_Boomer Sep. 18 at 11:14 PM
$PPBT 0.99 Down Gap?
0 · Reply
FBP
FBP Sep. 18 at 5:42 PM
$PPBT
0 · Reply
GildedAge01
GildedAge01 Sep. 18 at 5:27 PM
$PPBT what a scam !!!
0 · Reply
LuckyBoy27
LuckyBoy27 Sep. 18 at 4:35 PM
$PPBT these mgt bastards go to hell 🤬🤬🤬
0 · Reply
GildedAge01
GildedAge01 Sep. 18 at 1:19 PM
$PPBT this one headed to another reverse split lol
0 · Reply
martyn78
martyn78 Sep. 18 at 7:35 AM
Been tapped into @_ProfessorGamma for a minute now. The way they spot some of these plays before they run is nuts! Wise to be paying attention to this account, give him a proper follow 👍 $PPBT & $NVVE squeeze soon.
0 · Reply
Winorbust
Winorbust Sep. 17 at 11:02 PM
$PPBT lol you do realize it’s -not- 400% paid per day right? Not to mention I bet there is a discount on that borrow fee that you didn’t notice or care to say.
1 · Reply
haily_haily
haily_haily Sep. 17 at 4:52 PM
$PPBT next stop 1.20’s
0 · Reply